SELLAS Life Sciences CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institute
GFH009 to be Evaluated Against Pediatric Solid Tumors and Leukemia Models at Eight Participating Research Institutions.
United States Angelos Stergiou National Cancer Institute Jude Children Research Hospital Md Anderson Cancer Center Genfleet Therapeutics Shanghai Inc
Source: pressreleasepoint.com